Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tilavonemab Extension in Early Alzheimer's Disease
NCT03712787Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of tilavonemab in Alzheimer's disease (AD), sponsored by AbbVie Inc.. Started Mar 2019; status: terminated.
02
Drugs
tilavonemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03712787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712787.